	US 11,834,719 B2
	Genes and gene signatures for diagnosis and treatement of melanoma
Michael Bryan Warf, Salt Lake City, UT (US); Benjamin Roa, Salt Lake City, UT (US); Alexander Gutin, Salt Lake City, UT (US); and Darl Flake, Salt Lake City, UT (US)
Assigned to MYRIAD MYPATH, LLC, Salt Lake City, UT (US)
Filed by MYRIAD MYPATH, LLC, Salt Lake City, UT (US)
Filed on May 20, 2021, as Appl. No. 17/325,644.
Application 17/325,644 is a continuation of application No. 14/205,965, filed on Mar. 12, 2014, granted, now 11,021,752.
Claims priority of provisional application 61/889,609, filed on Oct. 11, 2013.
Claims priority of provisional application 61/793,031, filed on Mar. 15, 2013.
Prior Publication US 2022/0098670 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); G16B 20/00 (2019.01)

CPC C12Q 1/6886 (2013.01) [G16B 20/00 (2019.02); C12Q 2600/158 (2013.01)]

17 Claims

1. A method for treating melanoma in a patient, the method comprising:

measuring in a sample from the patient mRNA expression of a panel of genes normalized to one or more housekeeping genes, the panel of genes comprising a combination of:

PRAME;

S100-related genes S100A9, S100A7, S100A8, S100A12, and P13; and

one or more immune genes selected from CXCL9, CCL5, CXCL10, IRF1, PTPN22, PTPRC, LCP2, SELL, and CD38;

calculating a combined score of the measured mRNA expression of the panel of genes;

classifying the sample as being a malignant melanoma based on the combined score exceeding a reference value; and

administering to the patient having the malignant melanoma a treatment comprising one or more of:

excising the malignant melanoma;

excising the malignant melanoma and a border of normal skin,

reexcising the site of the sample to remove additional tissue;

reexcising additional tissue surrounding a biopsy site;

removal of a lymph node;

lymph node dissection;

chemotherapy;

radiation therapy;

biological therapy;

immunotherapy; and

targeted therapy.